The feasibility of using ursodeoxycholic acid in the treatment of patients with non-alcoholic fatty liver disease: a clinical case

Gastroenterologìa

Ye.S. Sirchak¹ 

[1] Uzhhorod National University, Uzhhorod, Ukraine;

关键词: non-alcoholic fatty liver disease;    treatment;    ursodeoxycholic acid;   

DOI  :  10.22141/2308-2097.52.3.2018.141848

来源: DOAJ

【 摘 要 】

Non-alcoholic fatty liver disease (NAFLD) is on a leading position among chronic liver diseases. In addition, the pathogenesis of NAFLD has not been fully studied for today. Some authors suggest that NAFLD is one of the components of metabolic syndrome (MS), considering it as a liver manifestation of MS. The article presents current views on the treatment of patients with NAFLD. The theoretical aspects of using ursodeoxycholic acid (UDCA) and the possibility of its application in patients with a combination of NAFLD and MS are also presented. As an example, the feasibility and efficacy of UDCA administration to the patient L. with NAFLD and MS (glucose intolerance, arterial hypertension, obesity) has been demonstrated. The prescription of Ursofalk to the patient L. is pathogenetically grounded due to the hypocholesterolemic, cytoprotective, antioxidant, anticholestatic and other its beneficial effects. UDCA can be considered as an effective and safe drug for the treatment of patients not only with NAFLD, but also with MS, diseases of the cardiovascular system and obesity.

【 授权许可】

Unknown